Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q2 FY23 results · Jul–Sep 2022
Panacea Biotec reported revenue from operations of ₹105.12 crore (down 54.7% from Q2 FY22) and net profit of ₹15.70 crore for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 105.12 | 232.17 | −54.7% | 110.70 | −5.0% |
| Other income | 10.45 | 2.03 | +414.8% | 12.21 | −14.4% |
| Total income | 115.57 | 234.20 | −50.7% | 122.91 | −6.0% |
| Profit before tax | 23.31 | (53.01) | Turned profit | (51.16) | Turned profit |
| Net profit for the period | 15.70 | (53.01) | Turned profit | (56.14) | Turned profit |
| EPS, basic (₹) | 2.56 | (8.65) | Turned profit | (9.17) | Turned profit |
| Net margin (%) | 14.9 | -22.8 | -50.7 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 48.74 | 119.26 | −59.1% | 61.34 | −20.5% |
| Other income | 7.92 | 3.47 | +128.2% | 6.53 | +21.3% |
| Total income | 56.66 | 122.73 | −53.8% | 67.87 | −16.5% |
| Profit before tax | (6.85) | (22.37) | Loss narrowed | (74.24) | Loss narrowed |
| Net profit for the period | (6.85) | (22.37) | Loss narrowed | (74.24) | Loss narrowed |
| EPS, basic (₹) | (1.12) | (3.65) | Loss narrowed | (12.12) | Loss narrowed |
| Net margin (%) | -14.1 | -18.8 | -121.0 |
Consolidated
- Filed with BSE
- 25 Nov 2022, 15:35 IST
- Board meeting
- 14 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Nov 2022, 15:35 IST
- Board meeting
- 14 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE